GBT Reports Fourth Quarter and Full Year 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Wall Street ends higher as tech rebounds before Nvidia results
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
- Oppenheimer Upgrades Capricor Therapeutics (CAPR) to Outperform 'on Approval Optimism'
- Dick's Sporting Goods (DKS) Misses Q2 EPS by 25c, Offers Guidance
Global Blood Therapeutics (GBT) PT Lowered to $67 at Cowen
February 24, 2022 6:55 AM ESTCowen analyst Ritu Baral lowered the price target on Global Blood Therapeutics (NASDAQ: GBT) to $67.00 (from $72.00) while maintaining an Outperform rating.
The analyst commented, "GBT reported Q4 Oxbryta sales of $56.1MM (+8% q/q), in line with guidance. NRxs were down... More
Global Blood Therapeutics (GBT) Misses Q4 EPS by 23c
February 23, 2022 5:06 PM ESTGlobal Blood Therapeutics (NASDAQ: GBT) reported Q4 EPS of ($1.36), $0.23 worse than the analyst estimate of ($1.13). Revenue for the quarter came in at $56.1 million versus the consensus estimate of $55.44 million.
For earnings history and earnings-related data on Global Blood Therapeutics (GBT) click here.
... More